WO2001056986A1 - New coupling process - Google Patents

New coupling process Download PDF

Info

Publication number
WO2001056986A1
WO2001056986A1 PCT/SE2001/000177 SE0100177W WO0156986A1 WO 2001056986 A1 WO2001056986 A1 WO 2001056986A1 SE 0100177 W SE0100177 W SE 0100177W WO 0156986 A1 WO0156986 A1 WO 0156986A1
Authority
WO
WIPO (PCT)
Prior art keywords
formula
compound
group
alkyl
reaction
Prior art date
Application number
PCT/SE2001/000177
Other languages
French (fr)
Inventor
Jörgen Alvhäll
Daniel Edvardsson
Panagiotis Ioannidis
Magnus Sjögren
Maria SZÖNYI
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to EP01904687A priority Critical patent/EP1257533A1/en
Priority to HU0300381A priority patent/HUP0300381A3/en
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Priority to NZ519946A priority patent/NZ519946A/en
Priority to KR1020027010158A priority patent/KR20020073202A/en
Priority to AU32516/01A priority patent/AU769009B2/en
Priority to JP2001556836A priority patent/JP2003521534A/en
Priority to SK1125-2002A priority patent/SK11252002A3/en
Priority to CA002396743A priority patent/CA2396743A1/en
Priority to IL15057301A priority patent/IL150573A0/en
Priority to PL01358006A priority patent/PL358006A1/en
Priority to BR0108130-6A priority patent/BR0108130A/en
Priority to MXPA02007388A priority patent/MXPA02007388A/en
Priority to US09/806,149 priority patent/US6518434B2/en
Publication of WO2001056986A1 publication Critical patent/WO2001056986A1/en
Priority to NO20023714A priority patent/NO20023714L/en
Priority to HK03101949.7A priority patent/HK1049836A1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D205/00Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/04Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members

Definitions

  • This invention relates to a novel process for the production of compounds comprising peptide linkages.
  • peptide linkages are typically formed via the coupling of an amine to a carboxylic acid.
  • Coupled reagents such as oxalyl chloride, EDC (l-(3- dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride) DCC
  • H ATU ([N,N,N',N'-tetramethyl-0-(benzotriazol-l -yl)uronium hexafluorophos- phate ])
  • H ATU (0-(azabenzotriazol- 1 -yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate) or TBTU ([N,N,N',N'-tetramethy]-0-(benzo- triazol- 1 -yl)uronium tetrafluoroborate]
  • an appropriate base
  • Such agents which are typically used to enhance the efficiency of the coupling reaction and/or the yield of the "coupled” product, have the disadvantage that they are expensive. Further, they may promote side- reactions and/or the formation of by-products, leading to a coupled product that has to be purified before it can be used, and/ or to unacceptable levels of chemical effluent being released into the environment.
  • a need ior an improved, cost-effective process for the formation of peptide linkages.
  • Such a process should preferably minimise the number of reagents that need to be employed, and thus the number of side-reactions and by-products that are formed and need to be removed prior to further processing of the coupled product.
  • NCAs N-carboxyanhydrides
  • peptide linkages may be formed by way of an efficient one-step process, in which NCAs are coupled directly to inter alia cyclic amino acid amide derivatives.
  • R.1 represents H or C1-.3 alkyl optionally substituted and/or terminated with one or more substituents selected from halo, cyano, nitro, S(0)2NH2, C(0)R 4 , C(0)OR 5 , SR6, S(0)R7.
  • R2 represents Ci .g alkyl, -A 1 -C4_g cycloalkyl or -A ⁇ -C . ⁇ Q aryl, all of which are optionally substituted by one or more substituents selected from C j_4 alkyl (which latter group is optionally substituted by one or more halo substituents), methylenedioxy, halo, cyano, nitro, S(0)2NH2, C(0)R4, C(0)OR 5 , SR 6 , S(0)R 7 , S(0)2R 8 , N(R9)RlO or 0 R1 1 ; R represents N(R12)R13 or CH(R ' 2)R13 ;
  • Rl 3 represents, at each occurrence, phenyl, C1.3 alkylphenyl or C(0)phenyl, all of which groups are optionally substituted by one or more substituents selected from cyano, amidino, hydroxyamidino, halo, Cj_4 alkyl (which group is optionally substituted by one or more halo group), SR 6 , N(R9)Rl 0 or OR ;
  • R9 and R ⁇ O independently represent, at each occurrence, H, C j _4 alkyl or C(0)R 14 ;
  • a ⁇ represents, at each occurrence, a single bond or C] _4 alkylene;
  • n represents 1 , 2 or 3;
  • R5 represents, at each occurrence, H, C1 -.5 alkyl or C ⁇ _3 alkylphenyl, which latter group is optionally substituted by one or more substituents selected from C] _4 alkyl (which latter group is optionally substituted by one or more halo substituents), methylenedioxy, halo, cyano, nitro, S(0)2NH2, C(0)R 4 , C(0)OR 5a , SR 6 , S(0)R 7 , S(0) 2 R 8 , N(R 9 )R ] 0 or OR 1 ] ;
  • R 4 , R ⁇ a , R 6 , RU , R ⁇ 2 and Rl 4 independently represent, at each occurrence, H or C 1.4 alkyl
  • R ' and R° independently represent, at each occurrence, C1 -.4 alkyl, which process comprises reaction of a compound of formula II,
  • Alkyl groups that R 1 , R 2 , R 4 , R 5 , R 5a , R 6 , R 7 , R 8 , R 9 , R 10 , R 1 1 , R 12 and R ⁇ 4 may represent, and with which R 2 , R5 and R 1 ⁇ may be substituted, may be linear or, when there is a sufficient number (i.e. three) of carbon atoms, be branched and/or cyclic. Further, when there is a sufficient number (i.e. four) of carbon atoms, such alkyl groups may also be part cyclic/acyclic. Such alkyl groups may also be saturated or, when there is a sufficient number (i.e. two) of carbon atoms, be unsaturated and/or interrupted by oxygen.
  • alkylphenyl groups that R5 and R 1 ⁇ may represent is at the alkyl part of such groups.
  • the alkyl part of such groups may be linear or, when there is a sufficient number (i.e. three) of carbon atoms, be branched.
  • Such alkyl parts may also be saturated or, when there is a sufficient number (i.e. two) of carbon atoms, be unsaturated and/or interrupted by oxygen.
  • Alkylene chains that A ⁇ may represent may be linear or, when there is a sufficient number (i.e. two) of carbon atoms, be branched. Such chains may also be saturated or, when there is a sufficient number (i.e. two) of carbon atoms, be unsaturated and/or interrupted by oxygen.
  • halo includes fluoro, chloro, bromo or iodo.
  • R* include C1.3 alkyl groups (e.g. an ethyl or, particularly a methyl group) substituted and/or terminated by a C(0)OR5 substituent, and, particularly, when the alkyl group is a C2-.3 alkyl group, those in which the optional C(0)OR ⁇ substituent is not located at the carbon atom to which the NH group is also attached.
  • Preferred values of R ⁇ include H, linear or branched C1 -.3 alkyl (e.g. tso-propyl or ethyl) or Cj_2 alkylphenyl (e.g. benzyl).
  • R 2 examples include -A I-C5.7 cycloalkyl or -A 1 -phenyl, in which, in both cases, A ⁇ represents a single bond or Cj _2 alkylene.
  • Particularly preferred R 2 groups include cyclohexyl.
  • R ⁇ examples include N(R l 2 )Rl 3 5 hich R l 2 represents C1.2 alkyl or, especially, H, and R 1 ⁇ represents C ⁇ _2 alkylphenyl (e.g. benzyl), which latter group is substituted with an amidino group, a hydroxyamidino group or, preferably, a cyano group, which substituent is preferably located at the 4-position on the phenyl part of that group (relative to the C ⁇ _2 alkyl part).
  • R 1 ⁇ represents C ⁇ _2 alkylphenyl (e.g. benzyl), which latter group is substituted with an amidino group, a hydroxyamidino group or, preferably, a cyano group, which substituent is preferably located at the 4-position on the phenyl part of that group (relative to the C ⁇ _2 alkyl part).
  • R 1 ⁇ represents an alkylphenyl group substituted at the phenyl part with amidino, hydroxyamidino or cyano
  • further such groups that may be mentioned include those that are also optionally substituted at the phenyl part with one or more halo (e.g. fluoro) atoms.
  • n 2 and, especially, 1.
  • the process of the invention is preferably carried out in the presence of an appropriate base and a suitable solvent system, which solvent system may comprise aqueous and/oi organic solvents.
  • a suitable solvent system which solvent system may comprise aqueous and/oi organic solvents.
  • the base and solvent system that are employed should not react chemically with, or give rise to stereochemical changes in, the reactants or product once formed, or give rise to other side reactions.
  • Suitable bases include inorganic bases, such as hydroxides, alkoxides, hydrogen carbonates or carbonates of alkali metals (such as Na or K), or organic bases, such as common tertiary amine bases (e.g. triethylamine, diisopropylefhylamine and N-methyl morpholine). Particularly preferred bases include amine bases.
  • Suitable aqueous solvents include water.
  • Suitable organic solvents include acetates (e.g. ethyl acetate, iso- ⁇ pro ⁇ pyl acetate, butyl acetate), acetonitrile, toluene, dichloromethane, tetrahydrofuran, dimethylformamide and mixtures of any of these solvents.
  • water is present in the solvent system that is employed.
  • the efficiency of the process is insensitive to the solid state properties of the amine of formula III that is employed.
  • NCA compounds of formula II are known in the art or may be prepared using conventional techniques (see, for example, the analogous processes described in German patent application DE 40 11 171 and international patent application WO 96/12729).
  • compounds of formula II may be prepared by reaction of an amino acid compound of formula IV, wherein Rl and R 2 are as hereinbefore defined, with phosgene.
  • This reaction may, for example, be carried out at elevated temperature (e.g. between 30°C and reflux temperature) in the presence of a suitable solvent, such as tetrahydrofuran.
  • Rl represents optionally substituted/terminated C ] _3 alkyl and which are optionally in the form of acid (e.g. hydrohalic acid) addition salts
  • acid e.g. hydrohalic acid
  • V an acid (e.g. a hydrohalic acid or an alkylsulphonic acid) addition salt thereof, with a compound of formula V,
  • R- a-L- V wherein L * represents a suitable leaving group (such as halo (e.g. Cl, Br or I), triflate, tosylate, mesylate, etc.) and R ⁇ a represents C 1 -.3 alkyl, optionally substituted and/or terminated with one or more substituents selected from halo, cyano, nitro, S(0) NH 2 , C(0)R 4 C(0)OR 5 , SR 6 , S(0)R 7 , S(0) R 8 , N(R9)Rl O or OR 1 1 and R 4 , R5, R6 ? R7 ⁇ R8 ? R9 ? R10 anc j R l l are as hereinbefore defined.
  • L * represents a suitable leaving group (such as halo (e.g. Cl, Br or I), triflate, tosylate, mesylate, etc.)
  • R ⁇ a represents C 1 -.3 alkyl, optionally substituted and/or terminated with
  • This reaction may, for example, be carried out at between room temperature and reflux temperature, in the presence of a suitable solvent system (e.g. aqueous and/or organic solvents (such as tetrahydrofuran, ethyl acetate, toluene, acetonitrile, etc.), including water/tetrahydrofuran mixtures and water/ethyl acetate mixtures), optionally in the presence of a base (e.g. an inorganic base, such as potassium hydrogen carbonate).
  • a suitable solvent system e.g. aqueous and/or organic solvents (such as tetrahydrofuran, ethyl acetate, toluene, acetonitrile, etc.), including water/tetrahydrofuran mixtures and water/ethyl acetate mixtures
  • a base e.g. an inorganic base, such as potassium hydrogen carbonate.
  • a suitable protecting group e.g. a benzy
  • compounds of formula IV in which Rl represents C ⁇ _3 alkyl substituted or terminated by C(0)OR ⁇ may be prepared by hydrogenation of a corresponding compound of formula IV in which R represents H in the presence of either a compound of formula VI,
  • Rib represents C(0)OR5 or C ⁇ _2 alkyl substituted or terminated by C(0)OR5 and R ⁇ is as hereinbefore defined
  • the R a groups either represent, separately, C1-.4 alkyl groups, or are joined together to form a C2-.4 alkylene chain, under appropriate reaction conditions.
  • Reaction of a compound of formula IV in which R 1 is H with a compound of formula VI, or a compound of formula VII, may, for example, be carried out in the presence of a suitable solvent system (e.g.
  • an alkyl alcohol such as methanol, ethanol, t-propanol or rc-propanol
  • an appropriate acid such as an inorganic acid (e.g. HC1) or an organic acid (e.g. methanesulphonic acid, toluenesulphonic acid etc).
  • these reactions may be carried out at around room temperature or above (e.g. up to the reflux temperature of the solvent that is employed (e.g. at around 40 to 60°C, such as about 50°C)), under hydrogen, for example under a positive pressure of hydrogen (e.g. 3 to 8 (e.g. 4 to 6, such as 5)) atmospheres, and in the presence of an appropriate hydrogenation catalyst system (e.g. Pd/C, Pt/C).
  • an appropriate hydrogenation catalyst system e.g. Pd/C, Pt/C
  • a process for the preparation of a compound of formula IV in which Rl represents C1.3 alkyl substituted or terminated by C(0)OR5 provided that, in the case of a C2-.3 alkyl group, the C(0)OR ⁇ group is not located at the carbon atom to which the NH group is also attached, which process comprises hydrogenation of a corresponding compound of formula IV in which Rl represents H in the presence of a compound of formula VI as hereinbefore defined, or a compound of formula VII as hereinbefore defined.
  • Substituents on the aryl (e.g. phenyl), and (if appropriate) heterocyclic, group(s) in compounds defined herein may be converted to other substituents using techniques well known to those skilled in the art.
  • amino may be converted to amido
  • amido may be hydrolysed to amino
  • hydroxy may be converted to alkoxy
  • alkoxy may be hydrolysed to hydroxy
  • cyano may be converted to amidino or hydroxyamidino.
  • the functional groups of intermediate compounds may be, or may need to be, protected by protecting groups.
  • Functional groups which it is desirable to protect thus include hydroxy, amino and carboxylic acid.
  • Suitable protecting groups for hydroxy include trialkylsilyl and diarylalkylsilyl groups (e.g. tert-butyldimethylsilyl, tert- butyldiphenylsilyl or trimethylsilyl), tetrahydropyranyl, benzyl and alkylcarbonyl groups (e.g. methyl- and ethylcarbonyl groups).
  • Suitable protecting groups for amino include benzyl, tert-butyloxycarbonyl, 9- fluorenylmethoxycarbonyl or benzyl oxycarbonyl.
  • Suitable protecting groups for carboxylic acid include C ⁇ . ⁇ alkyl, allyl or benzyl esters.
  • benzyl substituted (at the respective phenyl parts) by cyano may be converted to equivalent compounds of formula I in which the relevant phenyl group is substituted by an amidino, or, preferably, a hydroxyamidino, group under techniques known to those skilled in the art (e.g. using hydroxylamine).
  • the process of the invention is thus useful in the production of chemical compounds comprising peptide linkages and, in particular, peptide compounds comprising cyclic amino acid groups.
  • the process of the invention possesses the surprising advantage that peptide compounds of formula I may be obtained efficiently from readily-available starting materials without the need for the employment of coupling agents.
  • the process of the invention may have the advantage that compounds of formula I may be prepared in higher yields, in less time, more conveniently, and at a lower cost, than when prepared in processes described in the prior art.
  • reaction mixture was cooled to ambient temperature and then diluted with toluene (450 mL). The two phases were separated and the organic phase was washed with water twice, reduced, filtered and the product isolated as its hydrochloride salt, using hydrochloric acid in heptane. After drying, 199 g (93%) of the sub-title compound was obtained.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

Abstract

There is provided a process for the production of a compound of formula (I), which process comprises reaction of a compound of formula (II), with a compound of formula (III), wherein R1, R2, n and R3 have meanings given in the description.

Description

NEW COUPLING PROCESS
Field of the Invention
This invention relates to a novel process for the production of compounds comprising peptide linkages.
Prior Art
It is well known in the art that peptide linkages are typically formed via the coupling of an amine to a carboxylic acid.
Such coupling reactions are often carried out in the presence of so-called "coupling reagents", such as oxalyl chloride, EDC (l-(3- dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride) DCC
(dicyclohexylcarbodiimide), isobutyl chlorocarbonate, HBTU
([N,N,N',N'-tetramethyl-0-(benzotriazol-l -yl)uronium hexafluorophos- phate ]), H ATU (0-(azabenzotriazol- 1 -yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate) or TBTU ([N,N,N',N'-tetramethy]-0-(benzo- triazol- 1 -yl)uronium tetrafluoroborate]), and an appropriate base.
Such agents, which are typically used to enhance the efficiency of the coupling reaction and/or the yield of the "coupled" product, have the disadvantage that they are expensive. Further, they may promote side- reactions and/or the formation of by-products, leading to a coupled product that has to be purified before it can be used, and/ or to unacceptable levels of chemical effluent being released into the environment. Thus, there is a need ior an improved, cost-effective process for the formation of peptide linkages. Such a process should preferably minimise the number of reagents that need to be employed, and thus the number of side-reactions and by-products that are formed and need to be removed prior to further processing of the coupled product.
European patent applications EP 168 769 and EP 336 368, and US patent No. 5,359,086 disclose the coupling of N-carboxyanhydrides (NCAs) to cyclic amino acids, such as proline and esters thereof. There is no mention in these documents of the coupling of NCAs to cyclic amino acid amides.
We have found, surprisingly, that peptide linkages may be formed by way of an efficient one-step process, in which NCAs are coupled directly to inter alia cyclic amino acid amide derivatives.
Description of the Invention
According to a first aspect of the invention there is provided a process for the production of a compound of formula I,
Figure imgf000003_0001
wherein
R.1 represents H or C1-.3 alkyl optionally substituted and/or terminated with one or more substituents selected from halo, cyano, nitro, S(0)2NH2, C(0)R4, C(0)OR5, SR6, S(0)R7. S(0)2R8, N(R9)RlO 0r ORl ] ; R2 represents Ci .g alkyl, -A1-C4_g cycloalkyl or -A^-C .\Q aryl, all of which are optionally substituted by one or more substituents selected from C j_4 alkyl (which latter group is optionally substituted by one or more halo substituents), methylenedioxy, halo, cyano, nitro, S(0)2NH2, C(0)R4, C(0)OR5, SR6, S(0)R7, S(0)2R8, N(R9)RlO or 0R1 1 ; R represents N(R12)R13 or CH(R ' 2)R13 ;
Rl 3 represents, at each occurrence, phenyl, C1.3 alkylphenyl or C(0)phenyl, all of which groups are optionally substituted by one or more substituents selected from cyano, amidino, hydroxyamidino, halo, Cj_4 alkyl (which group is optionally substituted by one or more halo group), SR6, N(R9)Rl 0 or OR ;
R9 and R^ O independently represent, at each occurrence, H, C j _4 alkyl or C(0)R 14; A ^ represents, at each occurrence, a single bond or C] _4 alkylene; n represents 1 , 2 or 3;
R5 represents, at each occurrence, H, C1 -.5 alkyl or Cι _3 alkylphenyl, which latter group is optionally substituted by one or more substituents selected from C] _4 alkyl (which latter group is optionally substituted by one or more halo substituents), methylenedioxy, halo, cyano, nitro, S(0)2NH2, C(0)R4, C(0)OR5a, SR6, S(0)R7, S(0)2R8, N(R9)R] 0 or OR1 ] ;
R4, R^a, R6, RU , R^ 2 and Rl 4 independently represent, at each occurrence, H or C 1.4 alkyl; and
R ' and R° independently represent, at each occurrence, C1 -.4 alkyl, which process comprises reaction of a compound of formula II,
Figure imgf000004_0001
wherein R! and R2 are as defined above, with a compound of formula III,
Figure imgf000005_0001
wherein R3 and n are as defined above, and which process is referred to hereinafter as "the process of the invention".
Alkyl groups that R1 , R2, R4, R5, R5a, R6, R7, R8, R9, R10, R1 1 , R12 and RΪ4 may represent, and with which R2, R5 and R1^ may be substituted, may be linear or, when there is a sufficient number (i.e. three) of carbon atoms, be branched and/or cyclic. Further, when there is a sufficient number (i.e. four) of carbon atoms, such alkyl groups may also be part cyclic/acyclic. Such alkyl groups may also be saturated or, when there is a sufficient number (i.e. two) of carbon atoms, be unsaturated and/or interrupted by oxygen.
For the avoidance of doubt, the point of attachment of alkylphenyl groups that R5 and R1^ may represent is at the alkyl part of such groups. The alkyl part of such groups may be linear or, when there is a sufficient number (i.e. three) of carbon atoms, be branched. Such alkyl parts may also be saturated or, when there is a sufficient number (i.e. two) of carbon atoms, be unsaturated and/or interrupted by oxygen.
Alkylene chains that A^ may represent may be linear or, when there is a sufficient number (i.e. two) of carbon atoms, be branched. Such chains may also be saturated or, when there is a sufficient number (i.e. two) of carbon atoms, be unsaturated and/or interrupted by oxygen. As used herein, the term "halo" includes fluoro, chloro, bromo or iodo.
Preferred values of R* include C1.3 alkyl groups (e.g. an ethyl or, particularly a methyl group) substituted and/or terminated by a C(0)OR5 substituent, and, particularly, when the alkyl group is a C2-.3 alkyl group, those in which the optional C(0)OR^ substituent is not located at the carbon atom to which the NH group is also attached. Preferred values of R^ include H, linear or branched C1 -.3 alkyl (e.g. tso-propyl or ethyl) or Cj_2 alkylphenyl (e.g. benzyl).
Preferred values of R2 include -A I-C5.7 cycloalkyl or -A1 -phenyl, in which, in both cases, A^ represents a single bond or Cj _2 alkylene. Particularly preferred R2 groups include cyclohexyl.
Preferred values of R^ include N(Rl 2)Rl 35 hich Rl 2 represents C1.2 alkyl or, especially, H, and R 1^ represents Cι _2 alkylphenyl (e.g. benzyl), which latter group is substituted with an amidino group, a hydroxyamidino group or, preferably, a cyano group, which substituent is preferably located at the 4-position on the phenyl part of that group (relative to the C \ _2 alkyl part). When R1 ^ represents an alkylphenyl group substituted at the phenyl part with amidino, hydroxyamidino or cyano, further such groups that may be mentioned include those that are also optionally substituted at the phenyl part with one or more halo (e.g. fluoro) atoms.
Preferred values of n include 2 and, especially, 1.
The process of the invention is preferably carried out in the presence of an appropriate base and a suitable solvent system, which solvent system may comprise aqueous and/oi organic solvents. The base and solvent system that are employed should not react chemically with, or give rise to stereochemical changes in, the reactants or product once formed, or give rise to other side reactions.
Suitable bases include inorganic bases, such as hydroxides, alkoxides, hydrogen carbonates or carbonates of alkali metals (such as Na or K), or organic bases, such as common tertiary amine bases (e.g. triethylamine, diisopropylefhylamine and N-methyl morpholine). Particularly preferred bases include amine bases.
Suitable aqueous solvents include water. Suitable organic solvents include acetates (e.g. ethyl acetate, iso-propyl acetate, butyl acetate), acetonitrile, toluene, dichloromethane, tetrahydrofuran, dimethylformamide and mixtures of any of these solvents.
It is preferred that water is present in the solvent system that is employed. We have found, advantageously, that, when water is employed as a solvent, the efficiency of the process is insensitive to the solid state properties of the amine of formula III that is employed.
NCA compounds of formula II are known in the art or may be prepared using conventional techniques (see, for example, the analogous processes described in German patent application DE 40 11 171 and international patent application WO 96/12729).
For example, compounds of formula II may be prepared by reaction of an amino acid compound of formula IV,
Figure imgf000008_0001
wherein Rl and R2 are as hereinbefore defined, with phosgene. This reaction may, for example, be carried out at elevated temperature (e.g. between 30°C and reflux temperature) in the presence of a suitable solvent, such as tetrahydrofuran.
Compounds of formula IV, in which Rl represents optionally substituted/terminated C ] _3 alkyl and which are optionally in the form of acid (e.g. hydrohalic acid) addition salts, may be prepared by reaction of a corresponding compound of formula IV in which Rl is H, or an acid (e.g. a hydrohalic acid or an alkylsulphonic acid) addition salt thereof, with a compound of formula V,
R- a-L- V wherein L * represents a suitable leaving group (such as halo (e.g. Cl, Br or I), triflate, tosylate, mesylate, etc.) and R^ a represents C 1 -.3 alkyl, optionally substituted and/or terminated with one or more substituents selected from halo, cyano, nitro, S(0) NH2, C(0)R4 C(0)OR5, SR6, S(0)R7, S(0) R8, N(R9)Rl O or OR1 1 and R4, R5, R6? R7^ R8? R9? R10 ancj Rl l are as hereinbefore defined. This reaction may, for example, be carried out at between room temperature and reflux temperature, in the presence of a suitable solvent system (e.g. aqueous and/or organic solvents (such as tetrahydrofuran, ethyl acetate, toluene, acetonitrile, etc.), including water/tetrahydrofuran mixtures and water/ethyl acetate mixtures), optionally in the presence of a base (e.g. an inorganic base, such as potassium hydrogen carbonate). The skilled person will appreciate that it may be desirable to protect the carboxylic acid group of the respective compound of formula IV with a suitable protecting group (e.g. a benzyl group) before carrying out this reaction.
Compounds of formula IV in which Rl represents H and which are optionally in the form of acid (e.g. hydrohalic acid) addition salts may be prepared by hydrolysis of a corresponding compound of formula II in which Rl represents H under appropriate reaction conditions. The skilled person will appreciate that it may be possible and/or desirable to protect the carboxylic acid group of the resultant compound of formula IV with a suitable protecting group (e.g. a benzyl group) by performing this hydrolysis in the presence of a suitable protecting reagent (e.g. benzyl alcohol).
Alternatively, compounds of formula IV in which Rl represents Cι _3 alkyl substituted or terminated by C(0)OR^, provided that, in the case of a C2-.3 alkyl group, the C(0)OR5 group is not located at the carbon atom to which the NH group is also attached, may be prepared by hydrogenation of a corresponding compound of formula IV in which R represents H in the presence of either a compound of formula VI,
OHC-Rlb VI or a compound of formula VII,
Figure imgf000009_0001
in which, in both cases, Rib represents C(0)OR5 or Cι_2 alkyl substituted or terminated by C(0)OR5 and R^ is as hereinbefore defined, and, in the case of a compound of formula VII, the Ra groups either represent, separately, C1-.4 alkyl groups, or are joined together to form a C2-.4 alkylene chain, under appropriate reaction conditions. Reaction of a compound of formula IV in which R1 is H with a compound of formula VI, or a compound of formula VII, may, for example, be carried out in the presence of a suitable solvent system (e.g. an alkyl alcohol (such as methanol, ethanol, t-propanol or rc-propanol), which alcohol should be selected to avoid trans-esterification reactions in the reactants or products of the relevant reaction) and, optionally, an appropriate acid, such as an inorganic acid (e.g. HC1) or an organic acid (e.g. methanesulphonic acid, toluenesulphonic acid etc). The skilled person will appreciate that these reactions may be carried out at around room temperature or above (e.g. up to the reflux temperature of the solvent that is employed (e.g. at around 40 to 60°C, such as about 50°C)), under hydrogen, for example under a positive pressure of hydrogen (e.g. 3 to 8 (e.g. 4 to 6, such as 5)) atmospheres, and in the presence of an appropriate hydrogenation catalyst system (e.g. Pd/C, Pt/C). The skilled person will appreciate that altering the pressure of hydrogen during the relevant reaction will alter the reflux temperature of the solvent.
According to two further aspects of the invention, there is thus provided a process for the preparation of a compound of formula IV in which Rl represents C1.3 alkyl substituted or terminated by C(0)OR5 provided that, in the case of a C2-.3 alkyl group, the C(0)OR^ group is not located at the carbon atom to which the NH group is also attached, which process comprises hydrogenation of a corresponding compound of formula IV in which Rl represents H in the presence of a compound of formula VI as hereinbefore defined, or a compound of formula VII as hereinbefore defined.
These processes for the preparation of compounds of formula IV in which R represents Cι _3 alkyl substituted or terminated by C(0)OR5 may have the advantage that such compounds may be prepared in fewer steps than other processes for the piεparation of equivalent compounds of formula IV, which other processes are either described herein or may be described elsewhere in the prior art. In particular, this process avoids the need for protection of the relevant carboxylic acid group in a compound of formula IV in which Rl represents H prior to coupling with e.g. a compound of formula V, for example as described herein.
Compounds of formula III, V, VI and VII are either commercially available, are known in the literature, or may be obtained either by analogy with the processes described herein, or by conventional synthetic procedures, in accordance with standard techniques, from readily available starting materials using appropriate reagents and reaction conditions.
Substituents on the aryl (e.g. phenyl), and (if appropriate) heterocyclic, group(s) in compounds defined herein may be converted to other substituents using techniques well known to those skilled in the art. For example, amino may be converted to amido, amido may be hydrolysed to amino, hydroxy may be converted to alkoxy, alkoxy may be hydrolysed to hydroxy, and, where appropriate, cyano may be converted to amidino or hydroxyamidino.
It will be appreciated by those skilled in the art that, in the processes described above, the functional groups of intermediate compounds may be, or may need to be, protected by protecting groups. In particular, it may be desirable to protect the carboxylic acid functionality of a compound of formula IV (and acid addition salts thereof), with an appropriate protecting group (e.g. a benzyl group), which should be removed before reaction with phosgene.
Functional groups which it is desirable to protect thus include hydroxy, amino and carboxylic acid. Suitable protecting groups for hydroxy include trialkylsilyl and diarylalkylsilyl groups (e.g. tert-butyldimethylsilyl, tert- butyldiphenylsilyl or trimethylsilyl), tetrahydropyranyl, benzyl and alkylcarbonyl groups (e.g. methyl- and ethylcarbonyl groups). Suitable protecting groups for amino include benzyl, tert-butyloxycarbonyl, 9- fluorenylmethoxycarbonyl or benzyl oxycarbonyl. Suitable protecting groups for carboxylic acid include C\.β alkyl, allyl or benzyl esters.
The protection and deprotection of functional groups may take place before or after any of the reaction steps described hereinbefore.
Protecting groups may be removed in accordance with techniques which are well known to those skilled in the art and as described hereinafter.
The use of protecting groups is fully described in "Protective Groups in Organic Chemistry", edited by JWF McOmie, Plenum Press (1973), and "Protective Groups in Organic Synthesis", 3r(l edition, TW Greene & PGM Wutz, Wiley-Interscience (1999).
Compounds of formula I prepared by way of the process of the invention may be utilised in a subsequent peptide coupling reaction and/or may be converted to other compounds of formula I. For example, compounds of formula I wherein R^ represents N(R12)R135 jn which Rl represents phenyl, C(0)phenyl, or, preferably, C] _3 alkylphenyl (e.g. benzyl) substituted (at the respective phenyl parts) by cyano (e.g., in the case of C1-.3 alkylphenyl, at the 4-position relative to the Cj_3 alkyl part) may be converted to equivalent compounds of formula I in which the relevant phenyl group is substituted by an amidino, or, preferably, a hydroxyamidino, group under techniques known to those skilled in the art (e.g. using hydroxylamine). The process of the invention is thus useful in the production of chemical compounds comprising peptide linkages and, in particular, peptide compounds comprising cyclic amino acid groups.
The process of the invention possesses the surprising advantage that peptide compounds of formula I may be obtained efficiently from readily-available starting materials without the need for the employment of coupling agents.
Further, the process of the invention may have the advantage that compounds of formula I may be prepared in higher yields, in less time, more conveniently, and at a lower cost, than when prepared in processes described in the prior art.
The invention is illustrated, but in no way limited, by the following examples.
Example 1
Ethyl 2-[((lR)-2- {(2S)-2-[({4-cyanobenzyl}-amino)carbonyllazetidinyl}-l- cyclohexyl-2-oxoethyl)amino]acetate
(a) Benzyl (2R)-2-amino-2-cyclohexylethanoate methanesulfonate To a suspension of (2R)-2-amino-2-cyclohexylethanoic acid (200 g, 1.27 mol) and benzyl alcohol (276 g, 2.54 mol) in toluene (1600 mL) was added methanesulphonic acid at a rate which did not allow the temperature to reach 100°C. The reaction was stirred for an additional six hours at between 110 and 115°C. The water that was produced was distilled off using a Dean-Stark trap. An additional portion of benzyl alcohol (276 g, 2.54 mol) was added and the mixture was refluxed for a further twelve hours with water distillation. The reaction mixture was then cooled and methyl tert- butyl ether was added to initiate crystallisation. The product was filtered and dried to yield 404 g (92%) of the sub-title compound.
(b) Benzyl (2R)-2-cyclohexyl-2-[(2-ethoxy-2-oxoethyl)amino]ethanoate hydrochloride
To a suspension of KHCO3 (222 g, 2.22 mol) in water was added benzyl (2R)-2-amino-2-cyclohexylethanoate methanesulfonate (200 g, 0.58 mol, from step (a) above) in portions. After charging was completed, the mixture was stirred for 15 minutes at 20 to 25°C. The mixture was then diluted with tetrahydrofuran (150 mL) under continuous stirring for 30 minutes. Ethyl bromoacetate was added over one hour, whereupon the mixture was stirred for eight hours at 35°C. The temperature was then raised to 50°C and reacted for an additional four hours. The reaction mixture was cooled to ambient temperature and then diluted with toluene (450 mL). The two phases were separated and the organic phase was washed with water twice, reduced, filtered and the product isolated as its hydrochloride salt, using hydrochloric acid in heptane. After drying, 199 g (93%) of the sub-title compound was obtained.
(c) (2R)-2-Cyclohexyl-2-[(2-ethoxy-2-oxoethyl)amino]ethanoic acid
(Alternative A)
Benzyl (2R)-2-cyclohexyl-2 -[(2-ethoxy-2-oxoethyl)amino]ethanoate hydrochloride (40 g, 0.1 mol, from step (b) above) dissolved in 50-propyl alcohol (320 mL) was hydrogenated in the presence of 5% Pd/C (2 g, 50% aq.) for 3 h at 30°C. After removal of the catalyst by filtration, the filtrate was neutralised with tetrabutyl ammonium hydroxide and the pH was adjusted to 5.2. To rid the resultant of water, the suspension was evaporated and washed repeatedly with wo-propylalcohol and dried to yield 49 g (94%) of the sub-title compound.
(Alternative B) Ethylglyoxalate (50% in toluene; 71.5 g) was added to a mixture of (2R)-2- amino-2-cyclohexylethanoic acid (10 g; 64 mmol) and methanesulphonic acid (4.9 g; 0.51 mol) in ethanol (100 mL). The mixture was hydrogenated in the presence of 0.5 g of 5% Pd/C under a pressure of 5 atm. for 6 hours at 22°C. The mixture was then warmed to 50°C and hydrogenation was continued for an additional 14 hours. The catalyst was removed by filtration and the pH was adjusted to a value of between 4 and 5. Water (200 mL) was added to the resultant gelatinous slurry and the solid was filtered, washed and dried, giving 9.4 g (50%) of the sub-title compound as a white powder.
i H NMR (D20) δ 1.29 (t), ca. 1.1-1.4 (m), ca. 1.6-1.9 (m), ca. 2.0-2.2 (m), 4.04 (d), 4.08 (q), 4.31 (q)
13C NMR (D20) δ 13.9, 25.9, 26.1 , 26.3, 28.5, 29.0, 39.4, 47.6, 64.4, 66.1 , 167.7, 170.9
(d) Ethyl 2-[(4R)-4-cyclohexyl-2,5-dioxo-l,3-oxazolidin-3-yl]acetate Phosgene (28.9 kg, 291.9 mol) was added to (2R)-2-cyclohexyl-2-[(2- ethoxy-2-oxoethyl)amino]ethanoic acid (44.2 kg, 182 mol, obtained analogously to the method described in step (c) (Alternative A) above) in tetrahydrofuran (340 kg) at 40°C over one hour. The reaction was deemed to be complete after a further hour. The mixture was concentrated at reduced pressure. The residue was diluted with tetrahydrofuran (272.6 kg) and the pH was adjusted at 0°C to 6.5 with N-methylmorpholine (15.3 kg). The reaction was continued for a further 45 minutes. HCl/dioxane (0.34 kg) was then added and the residue was filtered through Celite®. The filter cake was washed twice with tetrahydrofuran. The combined filtrates were concentrated at reduced pressure at 20°C. To the residue was added heptane (250 kg), and the mixture was concentrated again. To the resultant residue further heptane (81 kg) was added. The temperature was adjusted to 0°C and the mixture was allowed to crystallise for five hours. The crystals were filtered, washed (3 x 30 kg heptane) and dried (low pressure, 20°C), to yield 46 kg (95%) of the sub-title compound.
13C NMR: δ 168.2, 167.9, 152.3, 65.3, 61.2, 43.8, 37.5, 27.3, 26.0, 25.6, 25.2, 13.9
(e) Ethyl 2-[(( 1 R)-2- 1 (2S)-2-[( { 4-cyanobenzyl } amino)carbonyl]azetidinyl j- - l -cyclohexyl-2-oxoethyl)amino]acetate
4-Methylmorpholine (4.9 g, 48.6 mmol) was added at 30°C to a mixture of (2S)-N-(4-cyanobenzyl)-2-azetidinecarboxamide (10.8 g, 43.9 mmol, prepared analogously to methods described generally in international patent applications WO 94/29336, WO 99/64391 and WO 00/12473) and ethyl 2- [(4R)-4-cyclohexyl-2,5-dioxo- l ,3-oxazolidin-3-yl]acetate ( 1 1.6 g, 42.2 mmol, see step (d) above) in ethyl acetate (28 mL). After five minutes of agitation, sodium chloride (aq., 9.3 mL, 10% w/w and 0.066% EDTA) was added. After an additional three hours of agitation, the organic layer containing the title compound was separated, yielding 99% of the desired compound.
3c ΝMR (CDC13): δ 14.3, 19.2, 26.1 , 26.2, 26.4, 29.2, 30.0, 41.1 , 42.9, 48.6, 49.5, 61 .0, 62.0, 62.8, 1 1 1 .1 , 1 18.9, 128.1 x 2, 132.5 x 2, 144.1 , 171.1 , 172.4. 175.7 Example 2
Ethyl 2-({(lR)-l-cyclohexyl-2-oxo-2-[(2S)-2-(2-phenylacetyl)azetidinyl]- ethyl } amino)acetate
To a solution of l-[(S)-azetidinyl]-2-phenyl-l-ethanone hydrochloride (9 g, 20 mmol) and ethyl 2-[(4R)-4-cyclohexyl-2,5-dioxo- l ,3-oxazolidin-3- yljacetate (6.7 g, 25 mmol, see Example 1(d) above) in ethyl acetate (50 mL) was added N-methyl morpholine (4 mL, 40 mmol). When the reaction was deemed to be complete according to HPLC, the reaction was worked up by extractions. Concentration gave 7 g of the title compound as an oil (84%).
LC-MS:(m+l ) = 417(m/z)
Example 3 Ethyl 2-[(( 15)-2- { (2R)-2-[( {4-[{[(benzyloxy)carbonyllamino} (hydroxy- imino)mefhyl]benzyl } amino)carbonyl]azetidinyl } - 1 -cyclohexyl-2- oxoethyl)amino]acetate
To a solution of benzyl [4-( {[(2S)azetidinylcarbonyl]amino}methyl)- phenyl](hydroxyimino)methylcarbamate hydrochloride ( 1 1.7 g, 25 mmol) and ethyl 2-[(4R)-4-cyclohexyl-2,5-dioxo-l ,3-oxazolidin-3-yl]acetate (6.7 g, 25 mmol, see Example 1(d) above) in tetrahydrofuran (55 mL) was added N-methyl morpholine (5 mL, 50 mmol). When the reaction was deemed to be complete according to HPLC, the reaction was filtered and worked up by extractions. Drying and concentration gave the desired compound as an oil (77%).
LC-MS:(m+l ) = 608 (m/z) Example 4
The following compound was prepared using analogous techniques to those described herein: ethyl 2- [(( 1 R)-2- { (2S)-2- [( { 4- [amino(hydroxyimino)methyl]benzyl } amino)- carbonyl] azetidinyl } - 1 -cyclohexyl-2-oxoethyl)amino]acetate di(trifluoromethanesulfonate) .

Claims

Claims
1. A process for the production of a compound of formula I,
Figure imgf000019_0001
wherein
Rl represents H or Cι _3 alkyl optionally substituted and/or terminated with one or more substituents selected from halo, cyano, nitro, S(0)2NH2, C(0)R4, C(0)OR5, SR6, S(0)R7, S(0) R8, N(R9)R10 0r OR1 ! ;
R2 represents Ci .g alkyl, -AI-C4.8 cycloalkyl or -A^-C .\Q aryl, all of which are optionally substituted by one or more substituents selected from C] _4 alkyl (which latter group is optionally substituted by one or more halo substituents), methylenedioxy, halo, cyano, nitro, S(0)2NH2, C(0)R4, C(0)OR5, SR6, S(0)R7, S(0)2R8, N(R9)RlO 0r OR1 * ; R3 represents N(R12)R! 3 or CH(Rl2)Rl3;
Rl3 represents, at each occurrence, phenyl, C1.3 alkylphenyl or C(0)phenyl, all of which groups are optionally substituted by one or more substituents selected from cyano, amidino, hydroxyamidino, halo, C] _4 alkyl (which group is optionally substituted by one or more halo group), SR6, N(R9)Rl0 or ORH ;
R9 and RlO independently represent, at each occurrence, H, Cj_4 alkyl or C(0)R14; Al represents, at each occurrence, a single bond or C1.4 alkylene; n represents 1, 2 or 3; R5 represents, at each occurrence, H, C\. alkyl or C 1.3 alkylphenyl, which latter group is optionally substituted by one or more substituents selected from C ]_4 alkyl (which latter group is optionally substituted by one or more halo substituents), methylenedioxy, halo, cyano, nitro, S(0)2NH2, C(0)R4,
C(0)OR5a, SR6, S(0)R7, S(0)2R8, N(R9)Rl O 0r OR1 ;
R4, R5a, R6, RU , R12 and Rϊ 4 independently represent, at each occurrence, H or Cj _4 alkyl; and
R7 and R8 independently represent, at each occurrence, C1.4 alkyl, which process comprises reaction of a compound of formula II,
Figure imgf000020_0001
wherein Rl and R2 are as defined above, with a compound of formula III,
Figure imgf000020_0002
wherein R3 and n are as defined above.
2. A process as claimed in Claim 1 , wherein Rl represents C1-.3 alkyl substituted and/or terminated by a C(0)OR5 substituent.
3. A process as claimed in Claim 2, wherein the C] _3 alkyl group is a methyl group or an ethyl group.
4. A process as claimed in any one of Claims 1 to 3 wherein R^ represents H, linear or branched C1-.3 alkyl or Cj_2 alkylphenyl.
5. A process as claimed in Claim 4 wherein R^ represents wo-propyl, ethyl or benzyl.
6. A process as claimed in any one of the preceding claims wherein R2 represents -AI-C5.7 cycloalkyl or -A 1 -phenyl, in which, in both cases, Al represents a single bond or Cι _2 alkylene.
7. A process as claimed in any one of the preceding claims wherein R3 represents N(R )R13, in which Rl2 represents H or Cj_2 alkyl and Rl3 represents Cι _2 alkylphenyl, which latter group is substituted with an amidino group, a hydroxyamidino group or a cyano group.
8. A process as claimed in Claim 7, wherein the substituent is located at the 4-position of the phenyl part of the Cj_2 alkylphenyl group (relative to the C}_2 alkyl part).
9. A process as claimed in any one of the preceding claims wherein the process is carried out in the presence of a base.
10. A process as claimed in Claim 9, wherein the base is a tertiary amine base.
11. A process as claimed in Claim 10, wherein the base is triethylamine, diisopropylethylamine or N-methyl morpholine.
12. A process as claimed in any one of the preceding claims wherein the reaction is carried out in the presence of a solvent system that includes water.
13. A process as claimed in any one of the preceding claims, wherein the reaction is carried out in the presence of an organic solvent, which is selected from an acetate, acetonitrile, toluene, dichloromethane, tetrahydrofuran, dimethyl formamide or a mixture of any of these solvents.
14. A process as claimed in any one of the preceding claims wherein the compound of formula II is prepared by reaction of a compound of formula IV,
Figure imgf000022_0001
wherein Rl and R2 are as defined in Claim 1 with phosgene.
15. A process as claimed in Claim 14, wherein, in the compound of formula IV, Rl represents optionally substituted/terminated C1.3 alkyl, the compound is optionally in the form of an acid addition salt, and the compound of formula IV is prepared by reaction of a corresponding compound of formula IV in which Rl is H, or an acid addition salt thereof, with a compound of formula V,
Rla.Ll V wherein L represents a leaving group and Rla represents C1.3 alkyl, optionally substituted and/or terminated with one or more substituents selected from halo, cyano, nitro, S(0)2NH2, C(0)R4 C(0)OR5, SR6, S(0)R7, S(0)2R8, N(R9)RlO 0r OR1 1 and R4 R5, R6, R7, R8, R9, R10 and Rl 1 are as defined in Claim 1.
16. A process as cl imed in Claim 14, wherein, in the compound of formula IV, Rl represents H, the compound is optionally in the form of an acid addition salt, and the compound of formula IV is prepared by hydrolysis of a corresponding compound of formula II, as defined in Claim 1 , in which Rl represents H.
17. A process as claimed in Claim 14, wherein, in the compound of formula IV, Rl represents C1 -.3 alkyl substituted or terminated by C(0)OR5, provided that, in the case of a C2-.3 alkyl group, the C(0)OR5 group is not located at the carbon atom to which the NH group is also attached, and the compound of formula IV is prepared by hydrogenation of a corresponding compound of formula IV in which Rl represents H in the presence of a compound of formula VI,
OHC-Rlb VI in which Rib represents C(0)OR5 or Cj_2 alkyl substituted or terminated by C(0)OR5 and R5 is as defined in Claim 1.
18. A process as claimed in Claim 14, wherein, in the compound of formula IV, Rl represents C1.3 alkyl substituted or terminated by C(0)OR5, provided that, in the case of a C2-3 alkyl group, the C(0)OR5 group is not located at the carbon atom to which the NH group is also attached, and the compound of formula IV is prepared by hydrogenation of a corresponding compound of formula IV in which Rl represents H in the presence of a compound of formula VII,
Figure imgf000023_0001
in which Rib is as defined in Claim 17 and the Ra groups either represent, separately, C .4 alkyl groups, or are joined together to form a C2-.4 alkylene chain.
19. A process for the preparation of a compound of formula IV as defined in Claim 14, in which Rl represents Cι _3 alkyl substituted or terminated by C(0)OR^, provided that, in the case of a C2-.3 alkyl group, the C(0)OR5 group is not located at the carbon atom to which the NH group is also attached, which process comprises hydrogenation of a corresponding compound of formula IV in which Rl represents H in the presence of a compound of formula VI as defined in Claim 17.
20. A process for the preparation of a compound of formula IV as defined in Claim 14, in which Rl represents C1 -.3 alkyl substituted or terminated by C(0)OR5, provided that, in the case of a C2-.3 alkyl group, the C(0)OR5 group is not located at the carbon atom to which the NH group is also attached, which process comprises hydrogenation of a corresponding compound of formula IV in which Rl represents H in the presence of a compound of formula VII as defined in Claim 18.
21. A process as claimed in any one of Claims 17 to 20, wherein, in the process step for the production of the compound of formula IV, the reaction is carried out in the presence of ethanol as solvent.
22. A process as claimed in any one of Claims 17 to 21 , wherein, in the process step for the production of the compound of formula IV, the reaction is carried out in the presence of an acid.
23. A process as claimed in Claim 22, wherein the acid is methanesulphonic acid.
24. A process as claimed in any one of Claims 17 to 23, wherein, in the process step for the production of the compound of formula IV, the reaction is carried out in the presence of a Pd/C or a Pt/C catalyst.
25. A process for the preparation of a compound of formula I wherein R3 represents N(R12)R13, in which Rl2 is as defined in Claim 1 and Rl3 represents phenyl, C(0)phenyl or C1 -.3 alkylphenyl, each of which are substituted by a hydroxyamidino group, which process comprises a process as claimed in any one of Claims 1 to 18, or any one of Claims 21 to 24 (as dependent on any one of Claims 1 to 18), in which, in the compound of formula III, R3 represents N(R12)R13, in which Rl2 is as defined in Claim 1 and Rl3 represents phenyl, C(0)phenyl or Cγ.T, alkylphenyl, each of which are substituted by a cyano group, followed by reaction of the resultant compound of formula I with hydroxylamine.
26. A compound of formula II as defined in any one of Claims 2 to 6.
PCT/SE2001/000177 2000-02-07 2001-01-30 New coupling process WO2001056986A1 (en)

Priority Applications (15)

Application Number Priority Date Filing Date Title
IL15057301A IL150573A0 (en) 2000-02-07 2001-01-30 Process for the production of compounds comprising peptide linkage
CA002396743A CA2396743A1 (en) 2000-02-07 2001-01-30 New coupling process
NZ519946A NZ519946A (en) 2000-02-07 2001-01-30 One-step coupling process for forming peptide linkages
HU0300381A HUP0300381A3 (en) 2000-02-07 2001-01-30 New coupling process
AU32516/01A AU769009B2 (en) 2000-02-07 2001-01-30 New coupling process
JP2001556836A JP2003521534A (en) 2000-02-07 2001-01-30 New coupling method
PL01358006A PL358006A1 (en) 2000-02-07 2001-01-30 New coupling process
EP01904687A EP1257533A1 (en) 2000-02-07 2001-01-30 New coupling process
KR1020027010158A KR20020073202A (en) 2000-02-07 2001-01-30 New coupling process
SK1125-2002A SK11252002A3 (en) 2000-02-07 2001-01-30 New coupling process
BR0108130-6A BR0108130A (en) 2000-02-07 2001-01-30 Processes for producing and preparing a compound, and, compound
MXPA02007388A MXPA02007388A (en) 2000-02-07 2001-01-30 New coupling process.
US09/806,149 US6518434B2 (en) 2000-02-07 2001-03-28 Coupling process
NO20023714A NO20023714L (en) 2000-02-07 2002-08-06 New linking process
HK03101949.7A HK1049836A1 (en) 2000-02-07 2003-03-17 New coupling process

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0000382-2 2000-02-07
SE0000382A SE0000382D0 (en) 2000-02-07 2000-02-07 New process

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US09/806,149 Continuation US6518434B2 (en) 2000-02-07 2001-03-28 Coupling process

Publications (1)

Publication Number Publication Date
WO2001056986A1 true WO2001056986A1 (en) 2001-08-09

Family

ID=20278363

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/SE2001/000177 WO2001056986A1 (en) 2000-02-07 2001-01-30 New coupling process

Country Status (20)

Country Link
US (1) US6518434B2 (en)
EP (1) EP1257533A1 (en)
JP (1) JP2003521534A (en)
KR (1) KR20020073202A (en)
CN (1) CN1227227C (en)
AU (1) AU769009B2 (en)
BR (1) BR0108130A (en)
CA (1) CA2396743A1 (en)
CZ (1) CZ20022675A3 (en)
HK (1) HK1049836A1 (en)
HU (1) HUP0300381A3 (en)
IL (1) IL150573A0 (en)
MX (1) MXPA02007388A (en)
NO (1) NO20023714L (en)
NZ (1) NZ519946A (en)
PL (1) PL358006A1 (en)
SE (1) SE0000382D0 (en)
SK (1) SK11252002A3 (en)
WO (1) WO2001056986A1 (en)
ZA (1) ZA200205235B (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003010142A2 (en) * 2001-07-24 2003-02-06 Adir A process for the preparation of perindopril, its analgous compounds and salts thereof using 2,5 -dioxo-oxazolidine intermediate compounds

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080249329A1 (en) * 2005-09-29 2008-10-09 Dsm Ip Assets B.V. Process For Esterification Of An Organic Acid
CN105384645A (en) * 2008-11-18 2016-03-09 因温斯特技术公司 1,2-diaminocyclohexane and chemical process

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1985002404A1 (en) * 1983-11-24 1985-06-06 Flork Michel New peptide derivatives, preparation process thereof and utilization thereof as biological reagents
EP0168769A2 (en) * 1984-07-16 1986-01-22 Merck & Co. Inc. Process for preparing carboxyalkyl dipeptides
EP0336368A2 (en) * 1988-04-04 1989-10-11 Kanegafuchi Kagaku Kogyo Kabushiki Kaisha N2-(1-carboxy-3-phenylpropyl)-L-lysine derivative and process of producing lysinopril using the compound
US5359086A (en) * 1992-09-16 1994-10-25 Krka, Pharmaceutical & Chemical Works Process for preparing alkyl-L-alanyl-L-proline derivatives

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH365385A (en) 1958-01-13 1962-11-15 Geigy Ag J R Process for the production of α-substituted glycines or glycine esters
GB1153792A (en) 1965-10-12 1969-05-29 Pfizer & Co C Pharmaceutical Compositions
SE372006B (en) 1971-09-13 1974-12-09 Haessle Ab
US3784562A (en) 1972-06-21 1974-01-08 Squibb & Sons Inc Methyl acetoacetic ester enamine of d-2-(1,4-cyclohexadien-1-yl)glycine, sodium salt-dimethylformamide adduct
DE2807286A1 (en) 1978-02-21 1979-08-23 Bayer Ag STEREOSELECTIVE CLEARANCE OF PHENYLGLYCINE DERIVATIVES AND 4-HYDROXYPHENYLGLYCINE DERIVATIVES WITH ENZYME RESINS
DE3003653A1 (en) 1980-02-01 1981-08-06 Hoechst Ag, 6000 Frankfurt N-substd. oxazolidine-2,4-di:one derivs. prodn. - by one-pot reaction of alkali cyanate with organic halide and alpha-hydroxy carboxylic acid ester
US4686295A (en) 1982-03-10 1987-08-11 Usv Pharmaceutical Corporation N-carboxy anhydride intermediates
DE3227055A1 (en) 1982-07-20 1984-01-26 Hoechst Ag, 6230 Frankfurt NEW DERIVATIVES OF 2-AZA-BICYCLO (2.2.2) OCTAN-3-CARBONIC ACID, METHOD FOR THE PRODUCTION THEREOF, THEIR SUBSTANCES AND THE USE THEREOF, AND 2-AZA-BICYCLO (2.2.2) OCTAN-3-CARBONIC ACID AS ANSWER FOR THEIR PRODUCTION
DE3303344A1 (en) 1983-02-02 1984-08-02 Hoechst Ag, 6230 Frankfurt METHOD FOR PRODUCING N-ALKYLATED AMINO ACIDS AND THEIR ESTERS
EP0174358A1 (en) 1984-03-01 1986-03-19 ALKALOIDA VEGYéSZETI GYáR Novel diastereomer salts of phenylalanine and n-acyl derivatives thereof and process for the separation of optically active phenylalanine and n-acyl derivatives thereof
GB8408801D0 (en) 1984-04-05 1984-05-16 Bp Chem Int Ltd Process for making esters
DE3623397A1 (en) 1986-07-11 1988-01-14 Boehringer Mannheim Gmbh NEW DIPHOSPHONIC ACID DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND MEDICINAL PRODUCTS CONTAINING THESE COMPOUNDS
GB8631020D0 (en) 1986-12-30 1987-02-04 Janssen Pharmaceutica Nv 1-methyl-1h-imidazole-5-carboxylic acid derivatives
JPS6445350A (en) 1987-08-13 1989-02-17 Sagami Chem Res Production of n-substituted-l-amino acid derivative
US4946942A (en) 1988-03-11 1990-08-07 Bioresearch, Inc. Urethane-protected amino acid-N-carboxyanhydrides
US5028693A (en) 1988-03-11 1991-07-02 Bioresearch, Inc. Urethane-protected amino acid-N-carboxyanhydrides
US4935328A (en) * 1988-04-07 1990-06-19 E. I. Du Pont De Nemours And Company Monofunctional amines as adjuvant for liquid electrostatic developers
DE4011171A1 (en) 1990-04-06 1991-10-10 Degussa PRODUCTION OF (ALPHA) -AMINO ACID-2,2,2, -TRIFLUORETHYLESTER
US5892112A (en) 1990-11-21 1999-04-06 Glycomed Incorporated Process for preparing synthetic matrix metalloprotease inhibitors
CA2056911C (en) 1990-12-11 1998-09-22 Yuuichi Nagano Hiv protease inhibitors
AU653060B2 (en) 1991-08-23 1994-09-15 Otsuka Pharmaceutical Co., Ltd. Carbostyril derivative and platelet agglutination inhibitor
US5610297A (en) 1991-12-27 1997-03-11 Georgia Tech Research Corp. Peptides ketoamides
GB9201755D0 (en) 1992-01-28 1992-03-11 British Bio Technology Compounds
TW223629B (en) 1992-03-06 1994-05-11 Hoffmann La Roche
GB9206757D0 (en) 1992-03-27 1992-05-13 Ferring Bv Novel peptide receptor ligands
NZ255300A (en) 1992-09-25 1997-05-26 Bio Mega Boehringer Ingelheim N-(hydroxyethyl)butane diamide derivatives, preparation and pharmaceutical compositions thereof
ZA951617B (en) 1994-03-04 1997-02-27 Lilly Co Eli Antithrombotic agents.
FR2725991B1 (en) 1994-10-24 1997-01-17 Univ Montpellier Ii PROCESS FOR PEPTIDE SYNTHESIS FROM N- (N '- (R') - N '-NITROSOCARBAMOYLS) AMINOACIDS
US5994583A (en) 1996-05-22 1999-11-30 The Scripps Research Institute Two step synthesis of D- and L- α-amino acids and D- and L- α-amino-aldehydes
CN1228083A (en) 1996-08-23 1999-09-08 美国辉瑞有限公司 Arylsulfonylamino hydroxamic acid derivatives
AR013084A1 (en) 1997-06-19 2000-12-13 Astrazeneca Ab USEFUL AMIDINE DERIVATIVES AS THROMBIN INHIBITORS, PHARMACEUTICAL COMPOSITION, USE OF SUCH COMPOUNDS FOR THE PREPARATION OF MEDICINES AND THE PROCESS FOR THE PREPARATION OF THE MENTIONED COMPOUNDS
DE19920907A1 (en) 1999-05-06 2000-11-09 Basf Ag Preparation of cyclohexylglycine ester derivatives comprises reacting cyclohexylglycine derivatives with methanesulfonic acid and benzyl alcohol derivative in organic solvent

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1985002404A1 (en) * 1983-11-24 1985-06-06 Flork Michel New peptide derivatives, preparation process thereof and utilization thereof as biological reagents
EP0168769A2 (en) * 1984-07-16 1986-01-22 Merck & Co. Inc. Process for preparing carboxyalkyl dipeptides
EP0336368A2 (en) * 1988-04-04 1989-10-11 Kanegafuchi Kagaku Kogyo Kabushiki Kaisha N2-(1-carboxy-3-phenylpropyl)-L-lysine derivative and process of producing lysinopril using the compound
US5359086A (en) * 1992-09-16 1994-10-25 Krka, Pharmaceutical & Chemical Works Process for preparing alkyl-L-alanyl-L-proline derivatives

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003010142A2 (en) * 2001-07-24 2003-02-06 Adir A process for the preparation of perindopril, its analgous compounds and salts thereof using 2,5 -dioxo-oxazolidine intermediate compounds
EP1279665A3 (en) * 2001-07-24 2003-03-12 Adir A process for the preparation of perindopril, its analogous compounds and salts thereof using 2,5-dioxo-oxazolidine intermediate compounds
WO2003010142A3 (en) * 2001-07-24 2003-08-28 Adir A process for the preparation of perindopril, its analgous compounds and salts thereof using 2,5 -dioxo-oxazolidine intermediate compounds

Also Published As

Publication number Publication date
HUP0300381A2 (en) 2003-06-28
HK1049836A1 (en) 2003-05-30
CA2396743A1 (en) 2001-08-09
BR0108130A (en) 2003-02-25
CN1398255A (en) 2003-02-19
NO20023714L (en) 2002-10-03
NZ519946A (en) 2004-11-26
NO20023714D0 (en) 2002-08-06
AU3251601A (en) 2001-08-14
CN1227227C (en) 2005-11-16
JP2003521534A (en) 2003-07-15
KR20020073202A (en) 2002-09-19
SK11252002A3 (en) 2003-02-04
US6518434B2 (en) 2003-02-11
HUP0300381A3 (en) 2005-06-28
PL358006A1 (en) 2004-08-09
CZ20022675A3 (en) 2002-11-13
IL150573A0 (en) 2003-02-12
MXPA02007388A (en) 2002-12-09
US20020128452A1 (en) 2002-09-12
SE0000382D0 (en) 2000-02-07
ZA200205235B (en) 2003-09-29
EP1257533A1 (en) 2002-11-20
AU769009B2 (en) 2004-01-15

Similar Documents

Publication Publication Date Title
KR101874557B1 (en) Method of preparing an inhibitor of cytochrome p450 monooxygenase, and intermediates involved
Lewis et al. A simple and efficient procedure for the preparation of chiral 2-oxazolidinones from α-amino acids
CZ302395B6 (en) Process for preparing (3R,4S)-l-(4-fluorophenyl)-3-[(3S)-3-(4-fluorophenyl)-3- hydroxypropyl)]-4-(4-hydroxyphenyl)-2-azetidinone
US7148355B2 (en) Process for the preparation of repaglinide
US6844440B2 (en) Process for the preparation of donepezil
US6518434B2 (en) Coupling process
AU770530B2 (en) Process for the production of N-protected azetidine-2-carboxylic acids (AzeOHs)
US20040082759A1 (en) Process for preparing distamycin derivatives
JP3285398B2 (en) Method for producing urethane compound
EP2044010B1 (en) New pharmaceutical intermediates in the synthesis of ace-inihibitors and the use thereof
JP4181233B2 (en) Method for producing pyrrolidine-2,4-dione derivative
KR101691353B1 (en) Manufacturing method for Bortezomib and new intermediate thereof
US6248903B1 (en) Process for the preparation of methyl (2s)-2-[(3r)-3-(n-{tert-butyloxycarbonyl 9-amino)-2-oxopyrrolidin-1-yl]propionate
KR100194158B1 (en) Method for preparing 1- (D-3-acetylthio-2-methylpropanoyl) -L-proline-L-phenylalanine
KR100566896B1 (en) Processes for the preparation of an optically active 5,6-dioxopiperazine-2-carboxylic acid derivative
WO2003051918A1 (en) Solution-phase process for the manufacture of decapeptide
JP2005154430A (en) Method for producing pyrimidine derivative, intermediate for the same, and method for producing the intermediate
JPWO2005042499A1 (en) Process for producing pyrimidine derivatives and intermediates
JPH07233138A (en) Method for producing n-alkoxycarbonylamino acid ester
EP1311481A1 (en) Process for preparing distamycin derivatives
JPH09255666A (en) Production of piperazinamide compound and piperazinamide derivative

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 09806149

Country of ref document: US

AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: IN/PCT/2002/00863/MU

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2002/05235

Country of ref document: ZA

Ref document number: 200205235

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 32516/01

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 519946

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 150573

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2396743

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: PA/a/2002/007388

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 11252002

Country of ref document: SK

WWE Wipo information: entry into national phase

Ref document number: PV2002-2675

Country of ref document: CZ

WWE Wipo information: entry into national phase

Ref document number: 018046347

Country of ref document: CN

ENP Entry into the national phase

Ref document number: 2001 556836

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 1020027010158

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 2001904687

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1020027010158

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: PV2002-2675

Country of ref document: CZ

WWP Wipo information: published in national office

Ref document number: 2001904687

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWG Wipo information: grant in national office

Ref document number: 32516/01

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 519946

Country of ref document: NZ

WWG Wipo information: grant in national office

Ref document number: 519946

Country of ref document: NZ